Immunovant Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $101.8M | $68.6M | $47.9M | $25.7M |
| SG&A Expense | $76.2M | $77.2M | $57.3M | $48.0M | $54.2M | $39.5M | $18.2M | $2.7M |
| Operating Income | $-505.4M | $-412.9M | $-258.8M | $-211.0M | $-156.8M | $-107.8M | $-65.7M | $-28.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | $0 | $625.0K | — |
| Pretax Income | $-505.4M | $-412.9M | $-258.8M | $-211.0M | $-156.8M | $-107.8M | $-66.3M | $-28.6M |
| Income Tax Expense | $215.0K | $891.0K | $567.0K | $9.0K | $-84.0K | $-358.0K | $97.0K | $19.0K |
| Net Income | $-505.6M | $-413.8M | $-259.3M | $-211.0M | $-156.7M | $-107.4M | $-66.4M | $-28.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-1.29 |
| EPS (Diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 | $-1.22 | $-1.54 | $-1.29 |
| Shares Outstanding (Basic) | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M | 87.8M | 81.8M | 38.6M |
| Shares Outstanding (Diluted) | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M | 87.8M | 81.8M | 38.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |